憩室炎治療の世界市場 - 2022年～2029年

当レポートでは、世界の憩室炎治療市場について調査し、市場の概要とともに、タイプ別、治療別、投与経路別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• タイプ別、市場内訳
• 治療別、市場内訳
• 投与経路別、市場内訳
• 流通チャネル別、市場内訳
• 地域別、市場内訳

第4章 市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 業界分析

• サプライチェーン分析
• 価格分析
• アンメットニーズ

第6章 COVID-19分析

第7章 タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、タイプ別
  • 市場魅力指数、タイプ別
• 憩室症
• 憩室炎
• その他

第8章 治療別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、治療別
  • 市場魅力指数、治療別
• 投薬
  • メトロニダゾール（フラギル）
  • トリメトプリム-スルファメトキサゾール（バクトリム）
  • シプロフロキサシン（Cipro）
  • クラブラン酸（オーグメンチン）
  • その他
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 手術
• 食物繊維
• その他

第9章 投与経路別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、投与経路別
  • 市場魅力指数、投与経路別
• 経口
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 静脈内

第10章 流通チャネル別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、流通チャネル別
  • 市場魅力指数、流通チャネル別
• 院内薬局
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 小売薬局
• オンライン薬局
• その他

第11章 地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク
• 注目すべき主要企業のリスト

第13章 企業プロファイル

• Pfizer Inc.
• G.D. Searle LLC
• Teva Pharmaceuticals USA, Inc.
• B. Braun Medical Inc.
• GlaxoSmithKline, Inc.
• Bayer HealthCare Pharmaceuticals Inc.
• Hoffmann-La Roche Inc.
• Hikma Pharmaceuticals USA Inc.

第14章 世界の憩室炎治療市場-DataM

Market Overview

The global diverticulitis disease treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Diverticulitis is the infection or inflammation of pouches that occurs in the intestines. These pouches aren't usually harmless. They might appear in the intestines at any time. Diverticulosis is the medical term for having them. Mild diverticulitis can be treated with rest, changes in your diet and antibiotics. Severe or recurring diverticulitis may require surgery.

Market Dynamics

New guidelines for treating uncomplicated acute diverticulitis are expected to drive market growth.

Nonantibiotic therapy is currently considered a valid technique for uncomplicated acute diverticulitis by recent guidelines from associations worldwide, including the American Society of Colorectal Surgeons. CT scan findings must be compatible with uncomplicated acute diverticulitis, and patients must not show signs of sepsis, according to clinical practice guidelines for the treatment of left-sided colonic diverticulitis (2020), the Second International Symposium on Diverticular Disease, held in Rome in 2016, and the 2020 WSES guidelines. Immunocompetent patients with simple diverticulitis who show no symptoms of systemic inflammation should not be treated with antibiotics, according to the WSES. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Lack of patient awareness in developing countries, stringent FDA guidelines for the approval of the latest treatment and side effects associated with the drugs are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Patients delayed critical therapy for diverticulitis during the early stages of the COVID-19 epidemic, resulting in more severe disease and death. During the early surge, patients who needed surgery urgently/emergently had extreme conditions and stayed longer than expected. Patients who had their planned procedures postponed were more likely to be readmitted to the hospital and require urgent or emergency surgery. Therefore, understanding the impact of COVID-19's early surgeon diverticulitis outcomes may help us better prepare for future surges, improve outcomes, and identify patients who may be able to avoid surgery. Thus, the above statements affected the market, which is expected to boost in the forecast period.

Segment Analysis

Medication segment is expected to hold the largest market share in diverticulitis disease treatment market

The medication segment is expected to dominate in 2021. The segment is further sub-segmented into antibiotic dugs. Besides, the segment benefits because antibiotics are utilized to treat infections that can occur in acute diverticulitis. For instance, Metronidazole (Flagyl), Trimethoprim-sulfamethoxazole (Bactrim), Ciprofloxacin (Cipro), Clavulanic acid (Augmentin) are some of the antibiotic drugs which are used in the treatment of acute diverticulitis. Therefore, it has increased the demand for drugs in diverticulitis disease treatment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global diverticulitis disease treatment market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing prevalence of obesity and smoking, rising demand for technologically advanced treatment, and growing public awareness of health issues in the region are factors the market is expected to boost in the forecast period. For instance, Overeating and physical inactivity are the two most common causes of obesity. Obesity is influenced by genetics, metabolism, environment, behavior, and culture, among other factors. The U.S. adult obesity rate stands at 42.4 percent, the first time the national rate has passed the 40 percent mark and further evidence of the country's obesity crisis.

Moreover, being Overweight affects more than one-third of men (34.1%) and one-quarter of women (27.5%). Obesity affects nearly half of all adults (42.4%). (including severe obesity). Severe obesity affects about one in every eleven persons (9.2%). The percentage of overweight men (34.1%) is higher than overweight women (33.4%). (27.5 percent ). Demand for services from the Weight Loss Services business is predicted to rise as the prevalence of adult obesity rises. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the diverticulitis disease treatment market are Pfizer Inc., G.D. Searle LLC, Teva Pharmaceuticals USA, Inc., B. Braun Medical Inc., GlaxoSmithKline, Inc., Bayer HealthCare Pharmaceuticals Inc., Hoffmann-La Roche Inc., Hikma Pharmaceuticals USA Inc.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its drugs and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

­Product Portfolio:

Flagyl Oral Formulation(metronidazole oral formulation): Metronidazole Oral Suspension is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected as the pathogen.

Why Purchase the Report?

Visualize the composition of the diverticulitis disease treatment market segmentation by type, treatment, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in diverticulitis disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of diverticulitis disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global diverticulitis disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market Snippet by Treatment
• 3.3. Market Snippet by Route of Administration
• 3.4. Market Snippet by Distribution channel
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. New guidelines for treating uncomplicated acute diverticulitis are expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Side effects associated with the drugs are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis
• 5.3. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Diverticulosis
• 7.3. Diverticulitis
• 7.4. Others

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment Segment
• 8.2. Medication*
  • 8.2.1. Metronidazole (Flagyl)
  • 8.2.2. Trimethoprim-sulfamethoxazole (Bactrim)
  • 8.2.3. Ciprofloxacin (Cipro)
  • 8.2.4. Clavulanic acid (Augmentin)
  • 8.2.5. Others
  • 8.2.6. Introduction
  • 8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Surgery
• 8.4. Dietary Fiber
• 8.5. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
• 9.2. Oral
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Intravenous

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 10.2. Hospital Pharmacy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Retail Pharmacy
• 10.4. Online Pharmacy
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Product Benchmarking
• 12.4. List of Key Companies to Watch

13. Company Profiles

• 13.1. Pfizer Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. G.D. Searle LLC
• 13.3. Teva Pharmaceuticals USA, Inc.
• 13.4. B. Braun Medical Inc.
• 13.5. GlaxoSmithKline, Inc.
• 13.6. Bayer HealthCare Pharmaceuticals Inc.
• 13.7. Hoffmann-La Roche Inc.
• 13.8. Hikma Pharmaceuticals USA Inc.

LIST NOT EXHAUSTIVE

14. Global Diverticulitis Disease Treatment Market - DataM

• 14.1. Appendix
• 14.2. About Us and Applications
• 14.3. Contact Us